Suppr超能文献

与遗传性表面活性物质蛋白B缺乏相关的先天性肺泡蛋白沉积症综合征的分子和表型变异性。

Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency.

作者信息

deMello D E, Nogee L M, Heyman S, Krous H F, Hussain M, Merritt T A, Hsueh W, Haas J E, Heidelberger K, Schumacher R

机构信息

Department of Pathology, St. Louis University, Missouri.

出版信息

J Pediatr. 1994 Jul;125(1):43-50. doi: 10.1016/s0022-3476(94)70119-9.

Abstract

Congenital alveolar proteinosis (CAP) is an often fatal cause of respiratory failure in term newborn infants, which has been associated with a genetic deficiency of surfactant protein B (SP-B) as a result of a frameshift mutation (121ins2) in a family with three affected siblings. In the index cases the deficiency of SP-B was associated with qualitative and quantitative abnormalities of the surfactant proteins A and C. Immunostaining for lung surfactant proteins and a search for the 121ins2 mutation by restriction enzyme analysis of DNA extracted from paraffin-embedded lung tissue was performed for 7 additional affected infants from 6 families, bringing to 10 the total number of patients with CAP who have been studied. In six infants, the surfactant protein immunostaining pattern was similar to that of the index cases. Of these, three patients were homozygous for the 121ins2 mutation; one was a compound heterozygote with the 121ins2 in one allele and a different mutation in the other; and three patients lacked the mutation in both alleles. One infant had an abundance of SP-B, suggesting phenotypic heterogeneity in CAP. Lung ultrastructural abnormalities, such as a reduced number of lamellar bodies, absent tubular myelin, and basal secretion of surfactant lipids and proteins, suggest a significant derangement of surfactant metabolism. The phenotypic heterogeneity in infants with CAP raises the possibility that variable degrees of SP-B deficiency may be more common than previously suspected.

摘要

先天性肺泡蛋白沉积症(CAP)是足月儿呼吸衰竭的常见致死原因,在一个有三名患病同胞的家庭中,由于移码突变(121ins2)导致表面活性物质蛋白B(SP-B)基因缺陷,CAP与之相关。在首例病例中,SP-B缺乏与表面活性物质蛋白A和C的定性及定量异常有关。对来自6个家庭的另外7名患病婴儿进行了肺表面活性物质蛋白免疫染色,并通过对石蜡包埋肺组织提取的DNA进行限制性酶切分析来寻找121ins2突变,这样一来,接受研究的CAP患者总数达到了10例。在6名婴儿中,表面活性物质蛋白免疫染色模式与首例病例相似。其中,3例患者121ins2突变呈纯合子状态;1例为复合杂合子,一个等位基因有121ins2突变,另一个等位基因有不同突变;3例患者两个等位基因均无该突变。1名婴儿有大量SP-B,提示CAP存在表型异质性。肺超微结构异常,如板层小体数量减少、管状髓鞘缺失以及表面活性物质脂质和蛋白的基底分泌,提示表面活性物质代谢存在显著紊乱。CAP婴儿的表型异质性增加了一种可能性,即不同程度的SP-B缺乏可能比之前怀疑的更为常见。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验